Navigation Links
West Concludes Agreement with Nektar
Date:2/13/2008

- Expects to Recover Investments in Dedicated Assets -

LIONVILLE, Pa., Feb. 13 /PRNewswire-FirstCall/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced that it has concluded an agreement with Nektar Therapeutics, Inc., relating to the manufacture and assembly of components for the Exubera(R) inhalable insulin device. Production of the device was suspended in October 2007 following Pfizer, Inc.'s decision to discontinue marketing the product, returning the marketing rights to the Company's customer, Nektar. Financial terms of the agreement were not disclosed.

Under the new agreement, West will be reimbursed for facility, inventory, raw materials and personnel costs at levels that are consistent with the Company's previously announced expectations. In order to assure Nektar of a reliable source of supply as it resolves its plans for the Exubera product, West has agreed to maintain the facility for a period of between two and ten months.

West expects to recognize an impairment charge of $12.9 million, in line with its previously disclosed estimate of between $11.0 million and $13.1 million, in the fourth quarter of 2007 for its investment in the Nektar contract.

West will announce its results for the fourth quarter and full year 2007 on February 21, 2008.

About West

West is a global manufacturer of components and systems for injectable drug delivery, including stoppers and seals for vials, and closures and disposable components used in syringe, IV and blood collection systems. The Company also provides products with application to the personal care, food and beverage markets. Headquartered in Lionville, Pennsylvania, West supports its partners and customers from 50 locations throughout North America, South America, Europe, Mexico, Japan, Asia and Australia. For more information, visit West at http://www.westpharma.com.
Exubera(R) is a registered trademark of Pfizer Inc.

Contacts:

West

Michael A. Anderson

Vice President and Treasurer

(610) 594-3345

Investors and Financial Media:

FD

Evan Smith / Theresa Kelleher

(212) 850-5600

wst@fd.com


'/>"/>
SOURCE West Pharmaceutical Services, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Workforce Alliance Concludes Three-Year Biotech Training Program
2. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
3. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
4. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
5. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
6. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
7. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
8. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
9. Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion
10. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
11. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... WonderWorks, ... NASA to showcase the future of deep space exploration and inspire space enthusiasts. ... Orion spacecraft and includes a guest appearance by former Shuttle Astronaut Don Thomas. ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... headlines and drive high-level conversations among healthcare industry stakeholders, the discussion surrounding the ... – taking place May 15-18, 2017 in Los Angeles, Calif. Hosted by the ...
(Date:4/25/2017)... April 25, 2017 Providence ... licensed its novel immune-modulating technology to an undisclosed global ... allergy. Tregitopes, pronounced T·rej·itopes, are a ... by EpiVax CEO Annie De Groot ... immunoglobulin G, an autoimmune disease therapy, Tregitopes are ...
(Date:4/24/2017)... NEW YORK , April 24, 2017  Dante Labs ... interpretation at only EUR 850 (ca. $900). While American individuals ... marks the first time Europeans can access WGS below EUR ... which are crucial to leveraging genetic information to make informed ... more. ...
Breaking Biology Technology:
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):